Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients

MLA

Sattler, Arne, et al. “Impaired Humoral and Cellular Immunity after SARS-CoV-2 BNT162b2 (Tozinameran) Prime-Boost Vaccination in Kidney Transplant Recipients.” Journal of Clinical Investigation, vol. 131, no. 14, July 2021. EBSCOhost, https://doi.org/10.1172/JCI150175.

APA

Sattler, A., Schrezenmeier, E., Weber, U. A., Potekhin, A., Bachmann, F., Straub-Hohenbleicher, H., Budde, K., Storz, E., Pross, V., Bergmann, Y., Thole, L. M. L., Tizian, C., Holsken, O., Diefenbach, A., Schrezenmeier, H., Jahrsdorfer, B., Zemojtel, T., Jechow, K., Conrad, C., … Kotsch, K. (2021). Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. Journal of Clinical Investigation, 131(14). https://doi.org/10.1172/JCI150175

Chicago

Sattler, Arne, Eva Schrezenmeier, Ulrike A. Weber, Alexander Potekhin, Friederike Bachmann, Henriette Straub-Hohenbleicher, Klemens Budde, et al. 2021. “Impaired Humoral and Cellular Immunity after SARS-CoV-2 BNT162b2 (Tozinameran) Prime-Boost Vaccination in Kidney Transplant Recipients.” Journal of Clinical Investigation 131 (14). doi:10.1172/JCI150175.